View in English?
View in English?
View in English?
Western blot analysis of activated recombinant HER2/ErbB2 and HER1/EGFR tyrosine kinase proteins, using Phospho-HER2/ErbB2 (Tyr1248) (upper), EGF Receptor (D38B1) XP® Rabbit mAb #4267 (middle) or HER2/ErbB2 (29D8) Rabbit mAb #2165 (lower). Phospho-HER2/ErbB2 (Tyr1248) specifically detects phosphorylated HER2/ErbB2 but not phosphorylated HER1/EGFR.
Immunohistochemical analysis of frozen HCC827 xenograft, using Phospho-Her2/ErbB2 (Tyr1221/1222)(6B12) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma using HER2/ErbB2 (D8F12) XP® Rabbit mAb.
Western blot analysis of T47D and MCF7 cells untreated or treated with Neuregulin (100 ng/ml) for 5 minutes, using Phospho-HER2/ErbB2 (Tyr1248) Antibody (upper) or HER2/ErbB2 (D8F12) XP® Rabbit mAb #4290 (lower).
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, showing membrane localization, using Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded SK-BR-3 (Her2 high, left) and MCF7 cell pellets (Her2 low, right) using HER2/ErbB2 (D8F12) XP® Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded SkBr3 cell pellets untreated (left) EGF-treated (right) either untreated (top) or lambda-phosphatase-treated (bottom), using Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb.
Western blot analysis of extracts from SK-BR-3 and MCF7 cells using HER2/ErbB2 (D8F12) XP® Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human renal adenocarcinoma, using Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb in the presence of control peptide (left) or Phospho-HER2/ErbB2 (Tyr1221/1222) Blocking Peptide #1254 (right).
Immunohistochemical analysis of paraffin-embedded human NCI-H358 xenograft, using Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb.
Western blot analysis of extracts from cells expressing different activated tyrosine kinase proteins, using Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb (upper) or Phospho-Tyrosine mAb (P-Tyr-100) #9411 (lower). Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb specifically detects phosphorylated HER2/ErbB2 but not other phosphorylated tyrosine kinases.
Western blot analysis of activated recombinant HER2/ErbB2 and HER1/EGFR tyrosine kinase proteins, using Phospho-HER2/ErbB2 (Tyr1248) (upper), EGF Receptor (D38B1) XP® Rabbit mAb #4267 (middle) or HER2/ErbB2 (29D8) Rabbit mAb #2165 (lower). Phospho-HER2/ErbB2 (Tyr1248) specifically detects phosphorylated HER2/ErbB2 but not phosphorylated HER1/EGFR.
Immunohistochemical analysis of frozen HCC827 xenograft, using Phospho-Her2/ErbB2 (Tyr1221/1222)(6B12) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma using HER2/ErbB2 (D8F12) XP® Rabbit mAb.
Western blot analysis of T47D and MCF7 cells untreated or treated with Neuregulin (100 ng/ml) for 5 minutes, using Phospho-HER2/ErbB2 (Tyr1248) Antibody (upper) or HER2/ErbB2 (D8F12) XP® Rabbit mAb #4290 (lower).
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, showing membrane localization, using Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded SK-BR-3 (Her2 high, left) and MCF7 cell pellets (Her2 low, right) using HER2/ErbB2 (D8F12) XP® Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded SkBr3 cell pellets untreated (left) EGF-treated (right) either untreated (top) or lambda-phosphatase-treated (bottom), using Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb.
Western blot analysis of extracts from SK-BR-3 and MCF7 cells using HER2/ErbB2 (D8F12) XP® Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human renal adenocarcinoma, using Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb in the presence of control peptide (left) or Phospho-HER2/ErbB2 (Tyr1221/1222) Blocking Peptide #1254 (right).
Immunohistochemical analysis of paraffin-embedded human NCI-H358 xenograft, using Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb.
Western blot analysis of extracts from cells expressing different activated tyrosine kinase proteins, using Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb (upper) or Phospho-Tyrosine mAb (P-Tyr-100) #9411 (lower). Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb specifically detects phosphorylated HER2/ErbB2 but not other phosphorylated tyrosine kinases.
| Product # | Size | Price |
|---|---|---|
| 9923T | 1 Kit (3 x 20 µl) | $ 253 |
| Product Includes | Quantity | Applications | Reactivity | MW(kDa) | Isotype |
|---|---|---|---|---|---|
| Phospho-HER2/ErbB2 (Tyr1248) Antibody 2247 | 20 µl |
|
H M | 185 | Rabbit |
| Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb 2243 | 20 µl |
|
H M | 185 | Rabbit IgG |
| HER2/ErbB2 (D8F12) XP® Rabbit mAb 4290 | 20 µl |
|
H M | 185 | Rabbit IgG |
| Anti-rabbit IgG, HRP-linked Antibody 7074 | 100 µl |
|
Goat |
Product Information
The Phospho-HER2/ErbB2 Antibody Sampler Kit provides an economical means to evaluate the activation status of HER2/ErbB2, including the phosphorylation of Tyr1248 and Tyr1221/1222. The control HER2/ErbB2 antibody is also included. The kit contains enough primary antibodies to perform two Western blot experiments per primary antibody.
Each phospho-HER2/ErbB2 antibody recognizes only the phosphorylated form of HER2/ErbB2 at the indicated sites. The control HER2/ErbB2 receptor antibody recognizes both phosphorylated and nonphosphorylated forms of HER2/ErbB2.
Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr1248. Polyclonal antibodies are purified by protein A and peptide affinity chromatography. Monoclonal antibodies are produced by immunizing animals with synthetic peptides corresponding to residues surrounding tyrosines 1221/1222 and residues near the amino terminus of human ErbB2 protein.
The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity (1). While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members (2). Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers (3). Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase (4). ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway (1,5).
Explore pathways + proteins related to this product.
STRING - Known and Predicted Protein-Protein Interactions.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.
PhosphoSitePlus®
